MA55045A - Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah) - Google Patents

Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)

Info

Publication number
MA55045A
MA55045A MA055045A MA55045A MA55045A MA 55045 A MA55045 A MA 55045A MA 055045 A MA055045 A MA 055045A MA 55045 A MA55045 A MA 55045A MA 55045 A MA55045 A MA 55045A
Authority
MA
Morocco
Prior art keywords
release
mazindol
adhd
attention
extended
Prior art date
Application number
MA055045A
Other languages
English (en)
Inventor
Lewis P Amsel
Scott Brantley
Virginia Schmith
Alexander C Zwyer
Original Assignee
Nls Pharmaceutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/055048 external-priority patent/WO2017152974A1/fr
Application filed by Nls Pharmaceutics Ag filed Critical Nls Pharmaceutics Ag
Publication of MA55045A publication Critical patent/MA55045A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA055045A 2016-03-09 2017-03-08 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah) MA55045A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305600P 2016-03-09 2016-03-09
PCT/EP2016/055048 WO2017152974A1 (fr) 2016-03-09 2016-03-09 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)

Publications (1)

Publication Number Publication Date
MA55045A true MA55045A (fr) 2021-12-29

Family

ID=58710015

Family Applications (2)

Application Number Title Priority Date Filing Date
MA045840A MA45840A (fr) 2016-03-09 2017-03-08 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)
MA055045A MA55045A (fr) 2016-03-09 2017-03-08 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA045840A MA45840A (fr) 2016-03-09 2017-03-08 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)

Country Status (15)

Country Link
US (3) US11207271B2 (fr)
EP (2) EP3426232B1 (fr)
JP (2) JP7127832B2 (fr)
KR (1) KR102304743B1 (fr)
CN (2) CN109152740A (fr)
AU (2) AU2017230974B2 (fr)
CA (1) CA3016852C (fr)
ES (1) ES2884973T3 (fr)
IL (2) IL295519A (fr)
MA (2) MA45840A (fr)
MX (1) MX386417B (fr)
NZ (1) NZ745921A (fr)
PL (1) PL3426232T3 (fr)
PT (1) PT3426232T (fr)
WO (1) WO2017153846A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
EP3573602A4 (fr) 2017-01-26 2020-09-16 Triastek, Inc. Formes posologiques de libération contrôlée à des sites gastro-intestinaux spécifiques
KR20200085730A (ko) 2017-09-07 2020-07-15 엔엘에스-1 파마 아게 헤로인 의존성 및 물질 사용 장애에 대한 마진돌 치료
CN116270513A (zh) * 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
EP3976101A4 (fr) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. Méthodes de traitement de la fibrose faisant appel à des composés favorisant l'oxydation du glucose
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
KR20230028535A (ko) * 2020-06-30 2023-02-28 임브리아 파마슈티칼스, 인크. 트리메타지딘의 변형 형태의 변형 방출 제제

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855440A (en) 1988-02-16 1989-08-08 Sherex Chemical Company, Inc. Method for producing stabilized imidazoline derivatives
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
JP2001102172A (ja) 1999-09-30 2001-04-13 Idemitsu Kosan Co Ltd 有機エレクトロルミネッセンス素子
GB0009522D0 (en) 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
WO2002038133A2 (fr) 2000-11-10 2002-05-16 F. Hoffman-La Roche Ag Compositions hydrolytiquement instables
CN1579401A (zh) 2003-08-11 2005-02-16 李亦武 一种止咳平喘药物新剂型及制备方法
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
CN1593404A (zh) 2004-07-16 2005-03-16 南京亿华药业有限公司 甲硝唑双层叠合缓释片及其制备方法
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
PT1954241E (pt) * 2005-11-28 2012-06-01 Orexigen Therapeutics Inc Formulação de zonisamida de libertação sustentada
KR100752417B1 (ko) 2006-02-14 2007-08-28 대원제약주식회사 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
FR2899476B1 (fr) 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
CN1985823A (zh) 2006-11-21 2007-06-27 北京润德康医药技术有限公司 一种含有盐酸二甲双胍罗格列酮的缓释制剂及其制备方法
EP3090743A1 (fr) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Compositions pharmaceutiques
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
EP3335711A1 (fr) * 2010-03-31 2018-06-20 Supernus Pharmaceuticals, Inc. Formulations de mazindol
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders

Also Published As

Publication number Publication date
WO2017153846A3 (fr) 2017-10-12
AU2017230974A1 (en) 2018-09-20
US20210038521A1 (en) 2021-02-11
JP7127832B2 (ja) 2022-08-30
BR112018068143A2 (pt) 2019-07-30
MA45840A (fr) 2021-05-05
EP3426232A2 (fr) 2019-01-16
KR20190019044A (ko) 2019-02-26
PT3426232T (pt) 2021-08-31
CA3016852C (fr) 2021-03-23
ES2884973T3 (es) 2021-12-13
JP2022160647A (ja) 2022-10-19
KR102304743B1 (ko) 2021-09-24
WO2017153846A2 (fr) 2017-09-14
EP3426232B1 (fr) 2021-06-02
CA3016852A1 (fr) 2017-09-14
JP2019507771A (ja) 2019-03-22
IL261418A (en) 2018-10-31
CN116803379A (zh) 2023-09-26
PL3426232T3 (pl) 2022-01-10
MX386417B (es) 2025-03-18
NZ745921A (en) 2021-12-24
AU2022202771A1 (en) 2022-05-19
MX2018010864A (es) 2019-03-28
IL261418B (en) 2022-09-01
IL295519A (en) 2022-10-01
US11207271B2 (en) 2021-12-28
EP3928770A1 (fr) 2021-12-29
AU2017230974B2 (en) 2022-02-03
CN109152740A (zh) 2019-01-04
JP7504488B2 (ja) 2024-06-24
US20240165034A1 (en) 2024-05-23
US20220160639A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MA55045A (fr) Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)
EP3583596A4 (fr) Concentration d'audio à deux étages pour traitement audio spatial
EP3496666A4 (fr) Dispositifs et procédés pour le traitement d'une insuffisance valvulaire
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
EP3455205A4 (fr) Peptidomimétiques pour le traitement d'une infection à norovirus
JP2016028092A5 (fr)
EP3645044A4 (fr) Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, membre a5, pour le traitement du glaucome
JP2016065085A5 (fr)
EP3465212A4 (fr) Régulation du microbiote intestinal pour le traitement de troubles neurodégénératifs
EP3324973A4 (fr) Systèmes et procédés pour le traitement de l' il avec un photosensibilisateur
MX2018014028A (es) Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
EP3621600A4 (fr) Procédés pour le traitement d'un glioblastome récurrent (rgbm)
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3849573A4 (fr) Bactériothérapie contre proprionibacterium acnes pour le traitement de l'acné
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3749342A4 (fr) Bactériophage pour le traitement et la prévention de cancers associés à des bactéries
EP3419981A4 (fr) Polythérapies utilisées dans le traitement de l'amyotrophie spinale
EP3331526A4 (fr) Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine
LT3592355T (lt) Kx2-391/kx-01, skirtas naudoti aktininės keratozės gydymui